首页> 外文OA文献 >Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

【2h】

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

机译：STRIDE的免疫应答是sipuleucel-T（sip-T）并用恩扎鲁胺（enz）或顺式恩扎鲁胺（enz）联合给药治疗转移性去势抵抗性前列腺癌（mCRPC）的随机，II期，开放标签研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Charles G Drake; David Quinn; Robert Dreicer; Emmanuel Antonarakis; Neal Shore; John Corman; Raoul Concepcion; Christopher Pieczonka; Dwayne Campogan; Li-Qun Fan; Nancy Chang; Nadeem Sheikh; Daniel Petrylak;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) [J] . Charles G Drake, David Quinn, Robert Dreicer, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：STRIDE是sipuleucel-T（sip-T）并用恩扎鲁胺（enz）或顺式恩扎鲁胺（enz）联合给药治疗转移性去势抵抗性前列腺癌（mCRPC）的一项随机，II期，开放标签研究，来自STRIDE的免疫反应
2. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer [J] . Small Eric J., Lance Raymond S., Gardner Thomas A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第17期

机译：具有同时与顺序AbiraTerone醋酸盐的随机相二试验，醋酸乙酸乙酸乙酸乙酸乙酸盐抗血液抗性前列腺癌
3. 344?Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641) [J] . Julie Nicole Graff, Joseph Burgents, Li Wen Liang, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：344？相3试验Pembolizumab和苯甲甲酰胺与烯醇丁胺患者在转移性阉割前列腺癌（MCRPC）（Keynote-641）中
4. Immune response from STRIDE a randomized Phase II open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) [O] . Charles G Drake, David Quinn, Robert Dreicer, 2015

机译：STRIDE的免疫应答是sipuleucel-T（sip-T）并用恩扎鲁胺（enz）或顺式恩扎鲁胺（enz）联合给药治疗转移性去势抵抗性前列腺癌（mCRPC）的一项随机II期开放标签研究
5. CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) [O] . R. de Wit, G. Kramer, J.-C. Eymard, 2019

机译：卡：卡扎特（CBZ）vs AbiraTerone（ABI）或烯甲酰胺（ENZ）的随机，开放标签研究在转移性阉割前列腺癌中（MCRPC）

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

著录项

引文网络

相似文献

相关主题

期刊订阅